Lenvatinib acts as the salvage therapy for advanced hepatocellular carcinoma

被引：0
|
作者：
Hsieh, M-C. [1 ]
Su, Y-L. [2 ]
Chen, Y-Y. [2 ]
Liu, C-T. [2 ]
Chen, Y-H. [2 ]
Chiu, T-J. [2 ]
Pei, S-N. [3 ]
Wu, C-C. [4 ]
Rau, K-M. [1 ]
机构：
[1] E DA Canc Hosp, Oncol & Hematol, Kaohsiung, Taiwan
[2] Kaohsiung Chang Gung Mem Hosp, Oncol & Hematol, Kaohsiung, Taiwan
[3] Chiayi Chang Gung Mem Hosp, Oncol & Hematol, Chiayi, Taiwan
[4] Chang Gung Mem Hosp Kaohsiung, Internal Med, Kaohsiung, Taiwan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
182P
引用
收藏
页码：57 / 57
页数：1
相关论文
共 50 条
  • [31] Weight-based dosing of lenvatinib for advanced hepatocellular carcinoma
    Ogasawara, Sadahisa
    Ooka, Yoshihiko
    Kato, Naoya
    HEPATOBILIARY SURGERY AND NUTRITION, 2020, 9 (02) : 253 - 254
  • [32] Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
    Kenji Ikeda
    Masatoshi Kudo
    Seiji Kawazoe
    Yukio Osaki
    Masafumi Ikeda
    Takuji Okusaka
    Toshiyuki Tamai
    Takuya Suzuki
    Takashi Hisai
    Seiichi Hayato
    Kiwamu Okita
    Hiromitsu Kumada
    Journal of Gastroenterology, 2017, 52 : 512 - 519
  • [33] Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma
    Catalano, Martina
    Casadei-Gardini, Andrea
    Vannini, Gianmarco
    Campani, Claudia
    Marra, Fabio
    Mini, Enrico
    Roviello, Giandomenico
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (11) : 1353 - 1365
  • [34] The impact of lenvatinib on sarcopenia in patients with advanced unresectable hepatocellular carcinoma
    Praktiknjo, Michael
    Solano, Ana S. Pena
    Sadeghlar, Farsaneh
    Welchowski, Thomas
    Schmid, Matthias
    Moehring, Christian
    Zhou, Taotao
    Mahn, Robert
    Monin, Malte B.
    Meyer, Carsten
    Feldmann, Georg
    Brossart, Peter
    van Beekum, Cornelius
    Semaan, Alexander
    Matthaei, Hanno
    Manekeller, Steffen
    Sprinkart, Alois M.
    Nowak, Sebastian
    Luetkens, Julian
    Kalff, Joerg C.
    Strassburg, Christian P.
    Gonzalez-Carmona, Maria A.
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [35] Correction to: Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer
    A. Matrone
    A. Prete
    A. Nervo
    A. Ragni
    L. Agate
    E. Molinaro
    C. Giani
    L. Valerio
    E. Minaldi
    A. Piovesan
    R. Elisei
    Journal of Endocrinological Investigation, 2021, 44 : 2859 - 2859
  • [36] Therapy in Advanced Hepatocellular Carcinoma
    Javan, Hanna
    Dayyani, Farshid
    Abi-Jaoudeh, Nadine
    SEMINARS IN INTERVENTIONAL RADIOLOGY, 2020, 37 (05) : 466 - 474
  • [37] Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study
    Wang, Lijun
    Wang, Hongwei
    Cui, Yong
    Liu, Ming
    Jin, Kemin
    Xu, Da
    Wang, Kun
    Xing, Baocai
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [38] Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy
    Kazuki Ohya
    Tomokazu Kawaoka
    Maiko Namba
    Shinsuke Uchikawa
    Kenichiro Kodama
    Kei Morio
    Takashi Nakahara
    Eisuke Murakami
    Akira Hiramatsu
    Masataka Tsuge
    Masami Yamauchi
    Michio Imamura
    Kazuaki Chayama
    Hiroshi Aikata
    Scientific Reports, 9
  • [39] HYPOTHYROIDISM AS A PREDICTIVE FACTOR FOR GOOD CLINICAL OUTCOMES IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA UNDERGOING LENVATINIB THERAPY
    Shomura, Masako
    Okabe, Haruka
    Sato, Emi
    Shiraishi, Koichi
    Hirose, Shunji
    Tsuruya, Kota
    Arase, Yoshitaka
    Anzai, Kazuya
    Kagawa, Tatehiro
    HEPATOLOGY, 2020, 72 : 218A - 218A
  • [40] Real-World Effectiveness of First Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights
    de Castria, Tiago Biachi
    Kim, Richard
    PRAGMATIC AND OBSERVATIONAL RESEARCH, 2024, 15 : 79 - 87
12345